£5 Million Boost for London‑Based uMotif
uMotif, the London‑based company that turns clinical data into patient‑friendly, cloud‑ready nuggets, has just closed a Series A round. The haul? £5 million, led by longtime backer AlbionVC. Oslo‑based DNV‑GL and a handful of angel investors also chipped in.
Why This Matters
- Speedy Tech Roll‑Out – The cash will help uMotif crank out new features, making it even easier for researchers to run studies that let patients use their own phones, tablets or wearables.
- Territory Expansion – With the fresh funds, the team can push into fresh study types and areas that are super high‑demand.
- Life‑Saving Impact – Faster, more patient‑centric trials mean new therapies reach people sooner – a big win for those fighting chronic and rare diseases.
A New Era for Clinical Trials
Gone are the days when a patient had to book an appointment, drive to a hospital, and then wait for hours to fill out paperwork. Thanks to the pandemic, the industry went full‑tilt into decentralised, virtual study formats. Imagine this: a patient in Copenhagen, London, or Los Angeles can give consent and submit data right from their living room, all while sipping coffee. That’s the uMotif way.
The Secret Sauce
uMotif’s platform is not just a technical marvel – it’s a people‑first ecosystem. Its cloud‑based, scalable design is trusted by the world’s top pharma and biotech players. Why? Because it keeps thousands of participants super engaged, turning data collection into a breeze.
- 26 countries, 25+ therapeutic areas (think dermatology, rare diseases, oncology, cardiology)
- Clinical & real‑world studies rolled out simultaneously
- Higher volume, higher quality data – all thanks to an experience that feels like chatting with a best friend rather than a sterile lab setting
What the New Money Will Do
With the £5 million, uMotif will sharpen its software’s flexibility. It will support not only ongoing research but also experimental designs that push the envelope. The geographic funnel will widen: Europe, the US, and beyond.
CEO Bruce Hellman Speaks
“We’re thrilled to empower our customers to run patient‑centred studies. This funding will sprint us ahead and eventually help bring high‑quality, life‑changing therapies into patients’ hands faster.”
Comments from Investors
- Andrew Elder (AlbionVC): “Reliable patient data in trials is now essential. uMotif’s platform was built with patients in mind, making data capture intuitive and effective. This tool can revolutionise how quickly treatments reach millions.”
- Kaare Helle (DNV GL): “Digital transformation is the key to a more sustainable healthcare sector. uMotif’s platform supports cutting‑edge trial models while amplifying the patient voice. Their team is both responsive and passionate.”
Stay Updated
If you want the latest scoop on this post category straight to your device, subscribe now. Keep riding the wave of innovation in patient‑centric clinical research!
